The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan

Ting Chi Yeh, Hsi Che Liu, Lin Yen Wang, Shu Huey Chen, Wei Ying Lin, Der Cherng Liang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution. One patient who was treated by a different protocol was excluded. In total, 48 patients with de novo AML were enrolled in this study. Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications. Six patients with APL were treated consecutively with 2 protocols, TPOG-APL-97 and APL-2001. As of July 31, 2006, the remission rates were 79%, 92%, and 98% after 1, 2, and 3 courses of induction therapy, respectively. The 5-year overall survival was 64%±6.9% (SE), and the 5-year event-free survival was 60%±7.1%; for non-APL AML, the rates were 62%±7.5% and 59%±7.6%; for APL, 83±15.2 and 67±19.3%. Among the factors analyzed, a complete remission achieved after 1 course of induction therapy, lactate dehydrogenase

Original languageEnglish
Pages (from-to)826-831
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 2007
Externally publishedYes

Fingerprint

Clinical Protocols
Taiwan
Acute Myeloid Leukemia
Pediatrics
Acute Promyelocytic Leukemia
L-Lactate Dehydrogenase
Disease-Free Survival
Survival
Therapeutics

Keywords

  • Acute myeloid leukemia
  • Acute promyelocytic leukemia
  • Outcome
  • Protocol design
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. / Yeh, Ting Chi; Liu, Hsi Che; Wang, Lin Yen; Chen, Shu Huey; Lin, Wei Ying; Liang, Der Cherng.

In: Journal of Pediatric Hematology/Oncology, Vol. 29, No. 12, 12.2007, p. 826-831.

Research output: Contribution to journalArticle

Yeh, Ting Chi ; Liu, Hsi Che ; Wang, Lin Yen ; Chen, Shu Huey ; Lin, Wei Ying ; Liang, Der Cherng. / The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan. In: Journal of Pediatric Hematology/Oncology. 2007 ; Vol. 29, No. 12. pp. 826-831.
@article{a1ad283167ed446b8972dee861f1778a,
title = "The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan",
abstract = "From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution. One patient who was treated by a different protocol was excluded. In total, 48 patients with de novo AML were enrolled in this study. Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications. Six patients with APL were treated consecutively with 2 protocols, TPOG-APL-97 and APL-2001. As of July 31, 2006, the remission rates were 79{\%}, 92{\%}, and 98{\%} after 1, 2, and 3 courses of induction therapy, respectively. The 5-year overall survival was 64{\%}±6.9{\%} (SE), and the 5-year event-free survival was 60{\%}±7.1{\%}; for non-APL AML, the rates were 62{\%}±7.5{\%} and 59{\%}±7.6{\%}; for APL, 83±15.2 and 67±19.3{\%}. Among the factors analyzed, a complete remission achieved after 1 course of induction therapy, lactate dehydrogenase",
keywords = "Acute myeloid leukemia, Acute promyelocytic leukemia, Outcome, Protocol design, Treatment",
author = "Yeh, {Ting Chi} and Liu, {Hsi Che} and Wang, {Lin Yen} and Chen, {Shu Huey} and Lin, {Wei Ying} and Liang, {Der Cherng}",
year = "2007",
month = "12",
doi = "10.1097/MPH.0b013e31815a05aa",
language = "English",
volume = "29",
pages = "826--831",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan

AU - Yeh, Ting Chi

AU - Liu, Hsi Che

AU - Wang, Lin Yen

AU - Chen, Shu Huey

AU - Lin, Wei Ying

AU - Liang, Der Cherng

PY - 2007/12

Y1 - 2007/12

N2 - From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution. One patient who was treated by a different protocol was excluded. In total, 48 patients with de novo AML were enrolled in this study. Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications. Six patients with APL were treated consecutively with 2 protocols, TPOG-APL-97 and APL-2001. As of July 31, 2006, the remission rates were 79%, 92%, and 98% after 1, 2, and 3 courses of induction therapy, respectively. The 5-year overall survival was 64%±6.9% (SE), and the 5-year event-free survival was 60%±7.1%; for non-APL AML, the rates were 62%±7.5% and 59%±7.6%; for APL, 83±15.2 and 67±19.3%. Among the factors analyzed, a complete remission achieved after 1 course of induction therapy, lactate dehydrogenase

AB - From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution. One patient who was treated by a different protocol was excluded. In total, 48 patients with de novo AML were enrolled in this study. Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications. Six patients with APL were treated consecutively with 2 protocols, TPOG-APL-97 and APL-2001. As of July 31, 2006, the remission rates were 79%, 92%, and 98% after 1, 2, and 3 courses of induction therapy, respectively. The 5-year overall survival was 64%±6.9% (SE), and the 5-year event-free survival was 60%±7.1%; for non-APL AML, the rates were 62%±7.5% and 59%±7.6%; for APL, 83±15.2 and 67±19.3%. Among the factors analyzed, a complete remission achieved after 1 course of induction therapy, lactate dehydrogenase

KW - Acute myeloid leukemia

KW - Acute promyelocytic leukemia

KW - Outcome

KW - Protocol design

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=37349104605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349104605&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e31815a05aa

DO - 10.1097/MPH.0b013e31815a05aa

M3 - Article

VL - 29

SP - 826

EP - 831

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 12

ER -